Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 19Lymphoid 16Myeloid 7Other solid neoplasm 6Thoracic 2Gynecologic 2Dermatologic 2Tumor-Agnostic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × navitoclax × Gynecologic × Clear all
NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Sunnybrook Health Sciences Centre

Phase 1 Active not recruiting
36 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02591095 2019-03-19

MONAVI-1

Centre Francois Baclesse

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡